Introducing the Results of Phase 2 Clinical Trial, Four-Year Follow-Up,
and Real-World Patient Treatment with VC-101
PMDA Inspection of V-Cell Center in Japan Completed in September
Pursuing Both Technology Transfer and Direct Market Entry

VigenCell announced on the 7th that it will attend "BIO JAPAN 2026," held in Yokohama, Japan from October 7th to 9th, to explore business development and partnership opportunities with global pharmaceutical and biotechnology companies.


BIO JAPAN, which began in 1986, is a major event in the bio and healthcare sector and is celebrating its 40th anniversary this year. Approximately 1,500 companies related to healthcare, including pharmaceutical and biotechnology firms, are expected to participate in this year’s event. The event will be held at PACIFICO Yokohama in Yokohama, Kanagawa Prefecture, Japan.


VigenCell company logo image. VigenCell

VigenCell company logo image. VigenCell

View original image

At this event, VigenCell plans to hold partnering meetings with global pharmaceutical and biotechnology companies based on its experience in clinical trials and commercialization within the field of regenerative medicine, and will discuss potential business collaborations such as technology transfer and joint development for its major pipelines.


In particular, the company will focus on introducing its experience spanning from clinical development to actual patient treatment for the cell therapy VC-101 (VT-EBV-N), which is under development as a treatment for EBV-positive lymphoma.


The main results of the phase 2 clinical trial and the four-year follow-up data for VC-101 were presented as oral presentations this year at both the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) meetings. Since September, patient enrollment and treatment have begun in accordance with the approval of the advanced regenerative medicine treatment plan.


VigenCell will also present its own cell processing and GMP manufacturing facility, the "V-Cell Center," along with its next-generation cell therapy candidates VC-302 (for glioblastoma) and VC-420 (for hepatocellular carcinoma). Through these efforts, the company aims to showcase its technological and manufacturing capabilities in cell therapy and regenerative medicine and expand opportunities for global collaboration.


The company is also preparing to enter the Japanese regenerative medicine market. According to VigenCell, in September, an inspection team from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) visited Korea and conducted an inspection of the V-Cell Center.


Byun Pyungseok, CEO of VigenCell, stated, "VC-101 is a case that has been presented at global conferences for both phase 2 clinical and four-year follow-up results, and has translated into actual patient administration as Korea’s first advanced regenerative medicine treatment. Our greatest strength is our comprehensive experience from development to the clinical setting, and we believe Japan is the market where this experience is most relevant, so we have been preparing our foundation for entry, including manufacturing facility inspections."



He added, "To realize the value of VC-101 early, we will pursue various channels simultaneously—including technology transfer as well as direct entry into the market leveraging Japan’s advanced regenerative medicine system."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing